Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population

被引:3
|
作者
Patrizi, Sara [1 ]
Miele, Evelina [1 ]
Falcone, Lorenza [2 ,5 ]
Vallese, Silvia [2 ]
Rossi, Sabrina [2 ]
Barresi, Sabina [2 ]
Giovannoni, Isabella [2 ]
Pedace, Lucia [1 ]
Nardini, Claudia [1 ]
Masier, Ilaria [1 ]
Abballe, Luana [1 ]
Cacchione, Antonella [1 ]
Russo, Ida [1 ]
Di Giannatale, Angela [1 ]
Di Ruscio, Valentina [1 ]
Salgado, Claudia Maria [3 ]
Mastronuzzi, Angela [1 ]
Ciolfi, Andrea [4 ]
Tartaglia, Marco [4 ]
Milano, Giuseppe Maria [1 ]
Locatelli, Franco [1 ,6 ]
Alaggio, Rita [2 ]
机构
[1] Bambino Gesu Pediat Hosp, Oncohematol Cell Therapy Gene Therapies & Hemopoie, IRCCS, Rome, Italy
[2] Bambino Gesu Pediat Hosp, Pathol Unit, IRCCS, Rome, Italy
[3] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Div Pathol, Pittsburgh, PA USA
[4] Bambino Gesu Pediat Hosp, Mol Genet & Funct Genom, IRCCS, I-00146 Rome, Italy
[5] Azienda Sanit Terr Fermo Marche, Augusto Murri Hosp, Pathol Unit, Fermo, Italy
[6] Univ Cattolica Sacro Cuore, Dept Life Sci & Publ Hlth, Rome, Italy
关键词
Malignant peripheral nerve sheath tumors; DNA methylation; Sarcoma classifier; TRANSFORMATION; SUZ12;
D O I
10.1186/s13148-023-01621-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundMalignant peripheral nerve sheath tumors (MPNSTs) account for 3-10% of pediatric sarcomas, 50% of which occur in neurofibromatosis type 1 (NF1). Sporadic MPNSTs diagnosis may be challenging due to the absence of specific markers, apart from immunohistochemical H3K27me3 loss. DNA methylation (DNAm) profiling is a useful tool for brain and mesenchymal neoplasms categorization, and MPNSTs exhibit a specific DNAm signature. An MPNST-like group has recently been recognized, including pediatric tumors with retained H3K27me3 mark and clinical/histological features not yet well explored. This study aims to characterize the DNAm profile of pediatric/juvenile MPNSTs/MPNST-like entities and its diagnostic/prognostic relevance.ResultsWe studied 42 tumors from two groups. Group 1 included 32 tumors histologically diagnosed as atypical neurofibroma (ANF) (N = 5) or MPNST (N = 27); group 2 comprised 10 tumors classified as MPNST-like according to Heidelberg sarcoma classifier. We performed further immunohistochemical and molecular tests to reach an integrated diagnosis. In group 1, DNAm profiling was inconclusive for ANF; while, it confirmed the original diagnosis in 12/27 MPNSTs, all occurring in NF1 patients. Five/27 MPNSTs were classified as MPNST-like: Integrated diagnosis confirmed MPNST identity for 3 cases; while, the immunophenotype supported the change to high-grade undifferentiated spindle cell sarcoma in 2 samples. The remaining 10/27 MPNSTs variably classified as schwannoma, osteosarcoma, BCOR-altered sarcoma, rhabdomyosarcoma (RMS)-MYOD1 mutant, RMS-like, and embryonal RMS or did not match with any defined entity. Molecular analysis and histologic review confirmed the diagnoses of BCOR, RMS-MYOD1 mutant, DICER1-syndrome and ERMS. Group 2 samples included 5 high-grade undifferentiated sarcomas/MPNSTs and 5 low-grade mesenchymal neoplasms. Two high-grade and 4 low-grade lesions harbored tyrosine kinase (TRK) gene fusions.By HDBSCAN clustering analysis of the whole cohort we identified two clusters mainly distinguished by H3K27me3 epigenetic signature. Exploring the copy number variation, high-grade tumors showed frequent chromosomal aberrations and CDKN2A/B loss significantly impacted on survival in the MPNSTs cohort.ResultsWe studied 42 tumors from two groups. Group 1 included 32 tumors histologically diagnosed as atypical neurofibroma (ANF) (N = 5) or MPNST (N = 27); group 2 comprised 10 tumors classified as MPNST-like according to Heidelberg sarcoma classifier. We performed further immunohistochemical and molecular tests to reach an integrated diagnosis. In group 1, DNAm profiling was inconclusive for ANF; while, it confirmed the original diagnosis in 12/27 MPNSTs, all occurring in NF1 patients. Five/27 MPNSTs were classified as MPNST-like: Integrated diagnosis confirmed MPNST identity for 3 cases; while, the immunophenotype supported the change to high-grade undifferentiated spindle cell sarcoma in 2 samples. The remaining 10/27 MPNSTs variably classified as schwannoma, osteosarcoma, BCOR-altered sarcoma, rhabdomyosarcoma (RMS)-MYOD1 mutant, RMS-like, and embryonal RMS or did not match with any defined entity. Molecular analysis and histologic review confirmed the diagnoses of BCOR, RMS-MYOD1 mutant, DICER1-syndrome and ERMS. Group 2 samples included 5 high-grade undifferentiated sarcomas/MPNSTs and 5 low-grade mesenchymal neoplasms. Two high-grade and 4 low-grade lesions harbored tyrosine kinase (TRK) gene fusions. By HDBSCAN clustering analysis of the whole cohort we identified two clusters mainly distinguished by H3K27me3 epigenetic signature. Exploring the copy number variation, high-grade tumors showed frequent chromosomal aberrations and CDKN2A/B loss significantly impacted on survival in the MPNSTs cohort.ConclusionDNAm profiling is a useful tool in diagnostic work-up of MPNSTs. Its application in a retrospective series collected during pre-molecular era contributed to classify morphologic mimics. The methylation group MPNST-like is a 'hybrid' category in pediatrics including high-grade and low-grade tumors mainly characterized by TRK alterations.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Malignant Peripheral Nerve Sheath Tumor (MPNST) with Low Grade Histologic Features Is a Fully Malignant Neoplasm with Aggressive Behavior
    Caragea, M.
    Lazar, A.
    Wang, W-L
    MODERN PATHOLOGY, 2014, 27 : 13A - 13A
  • [42] EPIGENETIC REPROGRAMMING DRIVES MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) DE-DIFFERENTIATION AND TREATMENT RESISTANCE
    Vasudevan, Harish
    Lastella, Sydney
    Sale, Matthew
    Casey-Clyde, Timothy
    Demaree, Benjamin
    Delley, Cyrille
    Lucas, Calixto
    Magill, Stephen
    Liu, John
    Chen, William
    Braunstein, Steve
    Reddy, Alyssa
    Perry, Arie
    Jacques, Line
    Pekmezci, Melike
    Abate, Adam
    McCormick, Frank
    Raleigh, David
    NEURO-ONCOLOGY, 2021, 23 : 33 - 33
  • [43] Malignant Peripheral Nerve Sheath Tumor (MPNST) with Low Grade Histologic Features Is a Fully Malignant Neoplasm with Aggressive Behavior
    Caragea, M.
    Lazar, A.
    Wang, W-L
    LABORATORY INVESTIGATION, 2014, 94 : 13A - 13A
  • [44] Cytohistologic correlations of 24 malignant peripheral nerve sheath tumor (MPNST) in 17 patients:: The Institut Curie experience
    Klijanienko, J
    Caillaud, JM
    Lagacé, R
    Vielh, P
    DIAGNOSTIC CYTOPATHOLOGY, 2002, 27 (02) : 103 - 108
  • [45] Scalp malignant peripheral nerve sheath tumor (MPNST) with bony involvement and new bone formation: case report
    Garg, A
    Gupta, V
    Gaikwad, SB
    Mishra, NK
    Ojha, BK
    Chugh, A
    Sharma, MC
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2004, 106 (04) : 340 - 344
  • [46] Intraosseous malignant peripheral nerve sheath tumor (MPNST) of the thoracic spine - A rare cause of spinal cord compression
    Gnanalingham, K
    Bhattacharjee, S
    O'Neill, K
    SPINE, 2004, 29 (18) : E402 - E405
  • [47] Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas
    Guo, Jianman
    Chaney, Katherine E.
    Choi, Kwangmin
    Witek, Gabriela
    Patel, Ami V.
    Xie, Hong
    Lin, Danny
    Whig, Kanupriya
    Xiong, Yao
    Schultz, David C.
    Ratner, Nancy
    Field, Jeffrey
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (03): : 856 - +
  • [48] Involvement of PACAP/ADNP Signaling in the Resistance to Cell Death in Malignant Peripheral Nerve Sheath Tumor (MPNST) Cells
    Castorina, Alessandro
    Giunta, Salvatore
    Scuderi, Soraya
    D'Agata, Velia
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2012, 48 (03) : 674 - 683
  • [49] Pazopanib Monotherapy Leads to Complete Remission of a Refractory Malignant Peripheral Nerve Sheath Tumor (MPNST), a Case Report
    Edrees, N.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S490 - S491
  • [50] Involvement of PACAP/ADNP Signaling in the Resistance to Cell Death in Malignant Peripheral Nerve Sheath Tumor (MPNST) Cells
    Alessandro Castorina
    Salvatore Giunta
    Soraya Scuderi
    Velia D’Agata
    Journal of Molecular Neuroscience, 2012, 48 : 674 - 683